Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 36.30
+0.85 (2.40%)
May 29, 2026, 1:30 PM CST
Pharmosa Biopharm Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -385.09 | -383.85 | -166.65 | 8.46 | -266.51 | -256.48 |
Depreciation & Amortization | 34.12 | 31.48 | 25.81 | 23.32 | 12.7 | 11.79 |
Other Amortization | - | - | - | - | - | 0.01 |
Loss (Gain) From Sale of Assets | - | - | 0.34 | - | - | - |
Loss (Gain) on Equity Investments | 1.2 | 0.9 | -1.95 | -5.5 | -3.93 | -0.66 |
Stock-Based Compensation | 3.78 | 2.76 | 3.58 | 0.87 | 0.59 | 15.04 |
Other Operating Activities | -4.21 | -3.64 | -7.73 | - | -0.02 | -0.02 |
Change in Accounts Receivable | -3.46 | 2.64 | -4.65 | -1.18 | 0.03 | -0.14 |
Change in Inventory | 10.81 | 4.93 | -2.83 | -21.91 | - | - |
Change in Accounts Payable | 0.76 | 7.46 | 0.09 | 0.59 | - | 2 |
Change in Unearned Revenue | -30.35 | -6.89 | 11.71 | - | - | - |
Change in Other Net Operating Assets | -30.34 | -13.27 | 15.12 | 26.81 | -1.19 | -9.05 |
Operating Cash Flow | -402.78 | -357.48 | -127.16 | 31.45 | -258.31 | -237.51 |
Capital Expenditures | -156.3 | -118.7 | -165.27 | -81.46 | -10.16 | -3.06 |
Sale (Purchase) of Intangibles | -0.65 | -0.65 | -0.7 | -0.01 | -0.03 | -0.19 |
Investment in Securities | 394 | 369 | -869 | - | - | - |
Other Investing Activities | 5.5 | 6.52 | -4.6 | -1.4 | 0.02 | 8 |
Investing Cash Flow | 242.55 | 256.17 | -1,040 | -82.87 | -10.17 | 4.75 |
Short-Term Debt Repaid | - | - | - | - | - | -61 |
Long-Term Debt Repaid | - | -17.99 | -21.16 | -14.22 | -15.9 | -26.34 |
Total Debt Repaid | -18.68 | -17.99 | -21.16 | -14.22 | -15.9 | -87.34 |
Net Debt Issued (Repaid) | -18.68 | -17.99 | -21.16 | -14.22 | -15.9 | -87.34 |
Issuance of Common Stock | 1.59 | 1.1 | 963.26 | 367.18 | 495.42 | 367.02 |
Financing Cash Flow | -17.09 | -16.89 | 942.11 | 352.97 | 479.52 | 279.68 |
Foreign Exchange Rate Adjustments | -0.01 | -0.01 | 0.01 | 0 | 0.01 | - |
Net Cash Flow | -177.34 | -118.21 | -224.62 | 301.55 | 211.05 | 46.93 |
Free Cash Flow | -559.09 | -476.18 | -292.43 | -50.01 | -268.47 | -240.57 |
Free Cash Flow Margin | -809.56% | -707.88% | -174.51% | -15.90% | - | - |
Free Cash Flow Per Share | -4.33 | -3.69 | -2.31 | -0.44 | -2.73 | -2.83 |
Cash Interest Paid | 3.65 | 3.65 | 4.44 | 2.86 | 0.65 | 1.21 |
Cash Income Tax Paid | 2.09 | 2.09 | 2.94 | - | - | - |
Levered Free Cash Flow | -432.42 | -365.3 | -255.43 | -50.37 | -165.23 | -135.95 |
Unlevered Free Cash Flow | -431.09 | -363.99 | -253.92 | -48.59 | -164.83 | -135.19 |
Change in Working Capital | -52.59 | -5.13 | 19.44 | 4.31 | -1.15 | -7.19 |